Praxis Unveils Perimenopausal Depression Trial Data

  • Praxis Precision Medicines Inc PRAX has reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for perimenopausal depression (PMD).
  • PRAX-114 60 mg suspension formulation (n=6) for 14 days in an outpatient setting showed rapid and sustained improvements in menopausal and mood symptoms.
  • Results trended toward baseline following discontinuation of PRAX-114, suggesting the need for continued treatment. 
  • PRAX-114 was well tolerated, with no change in the overall PRAX-114 safety profile.
  • Treatment with PRAX-114 resulted in mean decreases from baseline at Day 15 of 60% in frequency of moderate-to-severe hot flashes and 68% in the total score of the Perimenopausal Depression Questionnaire.
  • Treatment with PRAX-114 resulted in mean decreases from baseline at Day 15 of 47% in the HAM-D total score, 65% in the HAM-A total score, and 40% in the Symptoms of Depression Questionnaire.
  • Praxis Precision plans to advance PRAX-114 to a Phase 2b study in women with menopausal and mood symptoms, with trial details to be disclosed by the end of 2021.
  • PRAX-114 is an extrasynaptic GABAA receptor preferring positive allosteric modulator.
  • Praxis ended Q2 with $339.2 million in cash, cash equivalents, and marketable securities.
  • Price Action: PRAX shares are down 6.01% at $12.97 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsdepression treatment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!